The Efficacy and Safety of a Qiliqiangxin Capsule Combined with Sacubitril/Valsartan in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis.

Wensheng Chen Huihua ChangXiaoqi WangYuanping Wang Yun-Tao Liu Dawei Wang

Published in: Evidence-based complementary and alternative medicine : eCAM (2023)

This study indicated that in CHF patients, on the basis of sacubitril/valsartan treatment, combination with QLQX can potentially enhance the total effective rate, improve LVEF and 6-MWD, and reduce LVEDD values, with good safety. However, considering the poor quality of the included studies, a multicenter, randomized, double-blind controlled study is needed for further confirmation.

Keyphrases

ejection fraction
double blind
placebo controlled
end stage renal disease
clinical trial
newly diagnosed
chronic kidney disease
randomized controlled trial
prognostic factors
cross sectional
combination therapy
study protocol
smoking cessation